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Editorial
Lung cancer still a long road ahead
N.M. Bleehen
Department ofClinical Oncology and Radiotherapeutics, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QQ, UK.
Lung cancer is the commonest cancer in the United King-
dom. There were 40,137 deaths from it in the UK in 1987,
the latest year for which mortality statistics are available, and
it accounts for 17% of all new cases registered and 25% of
all deaths due to cancer.
This high incidence is of course not limited to the UK.
Thus in the USA there are in excess of 100,000 deaths
annually (Brown & Kessler, 1988). Worldwide, over the past
20 years there has been a continuing increase in lung cancer
mortality (Parkin, 1989). Death rates from lung cancer have
more than doubled in women in many developed countries
and are likely to exceed those from breast cancer (Stanley &
Stjernsward, 1989).
Two papers published in this issue of the British Journal
ofCancer are of interest in the context of the overall national
incidence and mortality figures (Connolly et al., 1990;
Watkin et al., 1990). They address not only these two general
parameters as seen in two well documented regional cancer
registries (Yorkshire and Mersey), but also attempt to relate
them to methods of treatment and the changes seen over
recent years.
The third paper is a salutary warning against undue
optimism with respect to improvements in survival in small
cell-lung cancer (SCLC). This paper from the UK Cancer
Coordinating Committee for Research-Lung Cancer Sub-
committee (UKCCCR-LCS), demonstrates that long-term
survival, even for SCLC patients treated in a clinical trial
context, still remains dismal in spite of improvements over
the past 20 years (Souhami & Law, 1990).
The two regional registry series, although presented some-
what differently, lead to remarkably similar conclusions. It
should be noted that one of the databases records all those
cases registered during life (Yorkshire, YCRO), while the
other (Mersey) encompasses all cases, including those diag-
nosed and registered at death. This underestimates the total
YCRO registration by less than 10% but will have an impact
on the total denominator of cases analysed for individual
treatment strategies. Histological classifications and treat-
ment descriptions are also only generally comparable.
The overall incidence did not change much over their
respective study periods (1976-1983 for YCRO and
1974-1986 for Mersey). However, the increase in proportion
for females registered is in accord with recent national and
international trends (Stanley & Stjernsward, 1989).
A major difficulty in assessing many clinical trials is the
lack of information of their relevance to the disease as seen
in the whole population. This well known 'denominator'
problem resulting from case selection is particularly relevant
in lung cancer where only a very small percentage of all cases
are entered into clinical studies. Thus, only 3,681 cases of
SCLC were collected over 8 years from the trials that were
studied in the UKCCCR-LSC report. If one makes approx-
imated assumptions of 40,000 cases of lung cancer per year,
with 20% being SCLC, then the 3,681 cases only represent
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6% of all patients likely to have been diagnosed in the UK
during those 8 years. Even if this calculation represents an
underestimate of the number of all patients treated in UK
trials over that period the total is unlikely to be much higher.
For the other histological types of lung cancer (non-small cell
lung cancer, NSCLC) the proportion so studied in trials is
likely to be much less.
A valuable result of these two registry studies is our ability
to use these total registrations to study 'denominator' prob-
lems. Thus in Mersey only 40% of all the 24,636 cases
registered as lung cancer had histological confirmation of the
disease. This was seen to improve over the 13-year study
period from 42 to 51% (in 1974 and 1986, respectively). An
even greater increase, of 45-58%, in histological confirm-
ation was seen in the YCRO data over their shorter 8-year
study period. This considerable increase is largely ascribed to
the increase in the mean age of those in whom histology may
now be confirmed by fibre optic bronchoscopy.
A second component of the denominator effect is that even
patients with histological confirmation may not receive active
treatment. This is well demonstrated in these two series. In
Mersey only 61% of all those histologically confirmed (in-
cluding 60% of all SCLC) were given active treatment. This
represents 36% of the total of all the cases registered.
Although for YCRO comparable overall data are not pre-
sented, those for individual histological types are essentially
similar. Thus for squamous carcinoma around 60% received
active treatment. No overall data are presented for SCLC but
it is noted that the proportion of SCLC patients given
chemotherapy increased from 29% to 45% during the study
period.
Observations about changes in regional survival results in
the context of these new complete denominators are note-
worthy. Not surprisingly treated patients live longer than
untreated ones, but 17% of untreated squamous carcinoma
patients were alive at 1 year (Mersey) or around 5% un-
treated alive at 2 years (YCRO). These were presumably the
patients deemed of poorest prognosis at diagnosis. Such data
need to be remembered in assessing the value of palliative
treatments.
Clinical practice for NSCLC has essentially remained
unchanged over the study period. The trend towards more
surgery in patients aged over 70, and improved survival in
that age group is noted in the YCRO study. This is thought
to relate to improvements in surgical practice. While radio-
therapy and chemotherapy have largely retained their pallia-
tive role in NSCLC in the above two series, improvements in
radical radiotherapy techniques (e.g. by CHART; Dische &
Saunders, 1989) or chemotherapy (e.g. Gralla & Kris, 1988)
may modify this position in the future.
The treatment of SCLC remains one of more promise than
fulfilment. Thus a large specialist centre has recently reported
5-year survival of 2.5% following treatment (Osterlind et al.,
1988). This is not very different from those of 3.5% for
Mersey and of about 3.7% in the UKCCCR-LCS series.
These poor long-term results are seen in spite of some
improvements in the median and 2-year survival times over
the study period. The increasing impact of chemotherapy is
deemed to be responsible for the improvements. In the
regional studies participation in multicentre trials such as
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those conducted by the MRC have had both an educational
effect on clinical practice and a beneficial effect on short-term
survival parameters.
Questions on the role of surgery and chemotherapy in
SCLC have also been addressed. Surgery was reported as
being of less value than radiotherapy for limited disease
SCLC in an early MRC trial (Medical Research Council,
1966). However, subsequent improvements in chemotherapy
have raised questions about the role of radiotherapy and
revised views about the role of surgery. Several reports have
now demonstrated 5-year survivals for surgically treated
SCLC of greater than 10% (Shields, 1986). These are well in
excess of the 2.5-3.7% reported in the UKCCCR-LCSC. In
the Mersey study 5-year survival results for surgical cases
were 10% overall and 22.5% following lobectomy. In the
YCRO series a 2-year survival of 11% is reported. What is
particularly useful about these two reports is that these sur-
vivals can now be placed in the perspective of the total
denominator. In Merseyside 11% and in the YCRO series
6% of all registered SCLC underwent surgical resection. It is
also not clear how much was chemotherapy added to the
surgery to influence these results. In this context it should be
noted that 72/225 (32%) received both modalities in the
Mersey series. The impact of surgery alone as a treatment
modality for SCLC is therefore only a small one in the
overall incidence of that disease.
The question as to whether or not thoracic radiotherapy
improves results in limited disease remains an open one. The
role of radiotherapy is SCLC is overviewed in the UKC-
CCR-LSC study. It fails to demonstrate any difference in
the per cent of long-term survivors whether or not
radiotherapy was given. However, it is not a true metanalysis
as only one of the studies, which also included extensive
disease patients, addressed the question in a randomised way.
Many believe that thoracic radiotherapy does reduce local
recurrence and significantly increases 2-year survival in
limited disease, but few series report survival in large
numbers at a later time (reviewed by Bleehen, 1988). This
must therefore remain an open question.
The three papers in this issue contain many other aspects
of interest than are reviewed in this editorial. Certain general
conclusions can be made. Firstly, lung cancer remains a
major problem. Survival statistics show some trend towards
improvement over recent years, but is still poor for NSCLC
and very poor for SCLC. Secondly, many patients never get
active treatment. This may be linked with apathy or, alterna-
tively, some may believe, sensible selection. The systematic
use of prognostic indicators might help to reduce this lottery
(e.g. Abrams et al., 1988; Spiegelman et al., 1989). These can
define groups for whom intensive therapy is indicated and
others for whom brief courses of palliative care are all that is
sensible. Carefully conducted randomised studies will not
only help to define better curative treatments but also define
the minimal treatment required for palliation. Such studies
are now being conducted by groups such as the MRC Lung
Cancer Working Party for both SCLC and NCSLC.
Finally, at the risk of being boring one should recognise
that lung cancer is a preventable disease. In spite of the
welcome recent trend of a small reduction in the male
mortality rate, the overall female lung cancer rate is contin-
uing to rise. Anti-smoking programmes such as those being
conducted nationally, and the Smoke-free Europe pro-
gramme jointly adopted by WHO and the 'Europe Against
Cancer' of the European Community deserve our active sup-
port (WHO, 1987).
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